Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June.

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly (LLY) to $825 from $975 and keeps an ...

Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...

Oregon Health & Science University said a trained AI program can detect cancer of a larynx by picking up the distinct ...

The Clean Label Project tested store-bought coffee and found it is mostly free of harmful levels of toxins and contaminants, ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.